Gilteritinib

• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Administration of Gilteritinib to eliminate MRD in patients with AML and FLT3-ITD mutation. Pending
  2025-521875-30-00 Phase II 1 country Hellenic Society Of Hematology
• IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting
  2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Sequential Gilteritinib in Combination with Venetoclax and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut… Recruiting
  2023-507878-41-00 Phase II 1 country Technische Universitat Dresden
• STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem… Ended
  2023-504176-25-00 Phase I/II 1 country Centre Antoine Lacassagne
• FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme… Ended
  2022-501372-25-00 Phase II 1 country French Innovative Leukemia Organization
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended
  2022-502478-18-00 Phase II 11 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid… Ended
  2024-512469-15-00 Phase I/II 4 countries Astellas Pharma Global Development Inc.
• A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone… Ended
  2024-512474-98-00 Phase III 2 countries Astellas Pharma Global Development Inc.

Showing 1–9 of 9 trials